Skip to main content

$17 Billion HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 - ResearchAndMarkets.com

The "HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.

The global HIV drugs market exceeded a value of US$ 17 Billion in 2017.

One of the primary factors catalyzing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments.

Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Looking forward, the market value is projected to reach approximately US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during 2018-2023.

Market Summary:

  • Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
  • On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.

The competitive landscape of the market has also been examined with some of the key players being

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global HIV Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Distribution Channel

8 Market Breakup by Region

9 HIV Drugs Manufacturing Process

10 Competitive Landscape

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Merck & Co.
  • Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

For more information about this report visit https://www.researchandmarkets.com/research/7hlwwj/17_billion_hiv?w=4

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, HIV/AIDS Drugs

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.